Published online before print February 19, 2007, doi: 10.1161/01.HYP.0000259328.04159.90
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2007;49:885.)
© 2007 American Heart Association, Inc.
Original Articles |
Nitroxyl Anion Donor, Angeli’s Salt, Does Not Develop Tolerance in Rat Isolated Aortae
From the Department of Pharmacology and Centre for Vascular Health, Monash University, Clayton, Victoria, Australia.
Correspondence to Barbara Kemp-Harper, Department of Pharmacology and Centre for Vascular Health Initiative, School of Biomedical Sciences, Monash University, Clayton, Victoria 3800, Australia. E-mail Barbara.Kemp{at}med.monash.edu.au
The nitroxyl anion (HNO) is emerging as a novel regulator of cardiovascular function with therapeutic potential in the treatment of diseases such as heart failure. It remains unknown whether tolerance develops to HNO donors, a limitation of currently used nitrovasodilators. The susceptibility of the HNO donor, Angeli’s salt (AS), to the development of vascular tolerance was compared with the NO donors, glyceryl trinitrate (GTN) and diethylamine/NONOate (DEA/NO) in rat isolated aortae. Vasorelaxation to AS was attenuated (P<0.01) by the HNO scavenger L-cysteine, whereas the sensitivity to GTN and DEA/NO was decreased (P<0.01) by the NO· scavenger carboxy-[2-(4-carboxyphenyl)-4,4,5,5-tetramethyl-imidozoline-1-oxy-3-oxide]. The soluble guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxaline-1-one impaired responses to GTN
AS>>DEA/NO. Pretreatment with 10, 30, and 100 µmol/L of GTN for 60 minutes induced a 4- (P<0.05), 13- (P<0.01), and 48-fold (P<0.01) decrease in sensitivity to GTN, demonstrating tolerance development. In contrast, pretreatment with AS or DEA/NO (10, 30, and 100 µmol/L) did not alter their subsequent vasorelaxation. All of the nitrovasodilators (30 µmol/L) displayed a similar time course of vasorelaxation and cGMP accumulation over a 60-minute period. Unlike vasorelaxation, the magnitude of peak cGMP accumulation differed substantially: DEA/NO>>AS>GTN. GTN did not induce cross-tolerance to either AS or DEA/NO. In contrast, pre-exposure to DEA/NO, but not AS, caused a concentration-dependent attenuation (P<0.01) of GTN-mediated relaxation, which was negated by the protein kinase G inhibitor guanosine 3',5'-cyclic monophosphorothioate, 8-(4-chlorophenylthio)-,Rp-isomer, triethylammonium salt. In conclusion, vascular tolerance does not develop to HNO, nor does cross-tolerance between HNO and GTN occur. Thus, HNO donors may have therapeutic advantages over traditional nitrovasodilators.
Key Words: NO • nitroxyl anion • nitrate tolerance • vasorelaxation • vasculature • Angeli’s salt • glyceryl trinitrate
This article has been cited by other articles:
 |
|
 |
|
  A. Zeller, M. V. Wenzl, M. Beretta, H. Stessel, M. Russwurm, D. Koesling, K. Schmidt, and B. Mayer Mechanisms Underlying Activation of Soluble Guanylate Cyclase by the Nitroxyl Donor Angeli's Salt Mol. Pharmacol., November 1, 2009; 76(5): 1115 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Miller, M. M. Cherney, A. J. Lee, N. E. Francoleon, P. J. Farmer, S. B. King, A. J. Hobbs, K. M. Miranda, J. N. Burstyn, and J. M. Fukuto The Effects of Nitroxyl (HNO) on Soluble Guanylate Cyclase Activity: INTERACTIONS AT FERROUS HEME AND CYSTEINE THIOLS J. Biol. Chem., August 14, 2009; 284(33): 21788 - 21796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Favaloro and B. K. Kemp-Harper Redox variants of NO (NO{middle dot} and HNO) elicit vasorelaxation of resistance arteries via distinct mechanisms Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1274 - H1280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Paolocci and D. A. Wink The shy Angeli and his elusive creature: the HNO route to vasodilation Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1217 - H1220. [Full Text] [PDF]
|
|